A phase II study of thalidomide in patients with brain metastases from malignant melanoma

References

• Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res 2000; 10: 81–92
   PubMed Web of Science ®Google Scholar
• O'Day S, Atkins M, Weber J, Thompson J, Anderson C, Gonzalez R et al A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). ASCO 2005.
   Google Scholar
• Meier S. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004; 27: 145–9
   PubMedGoogle Scholar
• Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 573
   Google Scholar
• D‘Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082–5
   PubMed Web of Science ®Google Scholar
• Quilitz R, Pharm D. Thalidomide in oncology. The peril and the promise. Cancer Control, JMCC 1999; 6: 483–95
   PubMedGoogle Scholar
• Rajkumar SV. Thalidomide in the treatment of cell malignancies. J Clin Oncol 2001; 19: 3593–5
   PubMed Web of Science ®Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675–80
   PubMed Web of Science ®Google Scholar
• Meierhofer C, Wiedermann CJ. New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel 2003; 6: 92–9
   PubMed Web of Science ®Google Scholar
• Meierhofer C. Theoretical basis for the activity of thalidomide. BioDrugs 2001; 15: 681–703
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802–11
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Atitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999; 341: 1565–71
   PubMed Web of Science ®Google Scholar
• Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14: 635–40
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V. Thalidomide in cancer medicine. Ann Oncol 2004; 15: 1151–60
   PubMed Web of Science ®Google Scholar
• Richardson P. Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002; 53: 629–57
   PubMed Web of Science ®Google Scholar
• Kumar S. Thalidomid: Current role in the treatment of non-plasma cell malignancies. 12 2005;22:2477–88.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Zeldis J, Williams B, Thomas S, Elsayed M. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21: 319–30
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–81
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res 2004; 14: 57–62
   PubMed Web of Science ®Google Scholar
• Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, DiLeone LP, et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 2004; 14: 527–31
   PubMed Web of Science ®Google Scholar
• Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812–7
   PubMed Web of Science ®Google Scholar
• Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling. Crit Rev Oncol/Hematol 2004; 53: 241–52
   Google Scholar
• Brock C, Newlands E, Wedge S, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363–7
   PubMed Web of Science ®Google Scholar
• Tolcher A, Gerson S, Denis L, Geyer C, Hammond L, Patnaik A, et al. Marked inactivation of 06-alkylguanine-DNA alkyltransferase activity with protected temozolomide schedules. Br J Cancer 2003; 88: 1004–11
   PubMed Web of Science ®Google Scholar